Novel therapy for COPD

Expert Opinion on Investigational Drugs

Volumn 9, Issue 1, 2000, Pages 3-23

  Leckie, M J ^a   Bryan, S A ^a   Hansel, T T ^a   Barnes, P J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Adhesion molecule antagonists; Anti oxidants; Bronchitis; Bronchodilators; Chemokines; Chronic obstructive pulmonary disease; Corticosteroids; Cytokines; Emphysema; Inflammatory mediators; Leukotriene antagonists; Mucoregulators; Proteases; Retinoids

Indexed keywords

3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 6 (4 ACETAMIDOPHENYL) 1,2,3,4,4A,10B HEXAHYDRO 8,9 DIMETHOXY 2 METHYLBENZO[C][1,6]NAPHTHYRIDINE; AMFEBUTAMONE; ANTIBIOTIC AGENT; ATIZORAM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; DARIFENACIN; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEVALBUTEROL; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT; OXIDIZING AGENT; PICLAMILAST; PROTEINASE; REVATROPATE; ROLIPRAM; SALBUTAMOL; SALMETEROL; SIBENADET; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZARDAVERINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG TARGETING; HEADACHE; HUMAN; INCIDENCE; INFLAMMATION; INSOMNIA; LUNG FUNCTION; MACROPHAGE; NEUTROPHIL; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SMOKING CESSATION; SUSTAINED RELEASE PREPARATION;

EID: 0033987258     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.1.3     Document Type: Review

References (163)